Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study. (PubMed, Lung Cancer) - Sep 10, 2026 - "This rw-analysis showed that combination nivolumab+ipilimumab for uPM provided long-term durable clinical benefit, comparable to CheckMate-743, despite an older population, with subsequent therapies retaining efficacy, especially for epithelioid subtype. These findings support first-line nivolumab+ipilimumab standard-of-care and underscore the need to improve beyond second-line strategies."
Journal • Real-world evidence • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor • BAP1
|
|
; Alain Bakebe; Anne Madroszyk; Aurélien Gobert; Charles Naltet; Charles Ricordel; Christine Raynaud; Eric Pichon; Fleur-Marie Quillot; Gérard Zalcman; Hugo Picchi; Jean-Baptiste Assié; Jean-Marc Dot; Laurene Gavoille; Laurent Greillier; Lionel Falchero; Lise Thibonnier; Marie Tiercin; Marie Wislez; Marielle Sabatini; Matthieu Chasseray; Nadia Munsch; Olivier Bylicki; Olivier Molinier; Ophélie Cassuto; Rémy Largillier; Romain Corre; Thierry Chatellier; Thomas Pierret
|